logo

For the Inventor, By the Inventor

Thebarton, Australia

Bionomics Inc.


USPTO Granted Patents = 64

% Expired Patents = 29.7



Trademarks = 1

Forward Citations = 194

Loading Chart...
Loading Chart...

91 inventors (with patents filed for the assignee):

goldMedal Bernard Luke Flynn (25 out of 27 patents)

silverMedal Dharam Paul (16 out of 19 patents)

bronzeMedal Jonathan Bayldon Baell (13 out of 29 patents)

4.  Gabriel Kremmidiotis (13 out of 13 patents)

5.  Andrew John Harvey (12 out of 23 patents)

6.  Christopher L Reyes (10 out of 12 patents)

7.  Jason Hugh Chaplin (10 out of 11 patents)

8.  Peter Chu (9 out of 9 patents)

9.  Damian Wojciech Grobelny (9 out of 19 patents)

10.  Brad E Sleebs (9 out of 15 patents)

11.  Nurul Quazi (8 out of 10 patents)

12.  Rajinder Singh (8 out of 11 patents)

13.  Chinh Thien Bui (8 out of 12 patents)

14.  Samuel Frank Berkovic (8 out of 13 patents)

15.  Ian Phillip Street (7 out of 7 patents)


Core Competencies:
Therapeutic Formulations
Ion Channel Modulators
Anxiolytic Compounds
Monoclonal Antibodies
Cancer Treatment
Predictive Biomarkers
Combination Therapy
Tubulin Polymerisation Inhibitors
Potassium Channel Blockers
Receptor Modulating Compounds
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia

64 patents:

1. 12409140 - Therapeutic formulations and uses thereof (2025-09-09),
2. 12275732 - Cyclic compounds as receptor modulating therapeutics and methods and uses thereof (2025-04-14),
3. 12139473 - Substituted-N-heteroaryl compounds and uses thereof (2024-11-12),
4. 12090146 - Substituted-pyridinyl compounds and uses thereof (2024-09-17),
5. 11884673 - Modulators of ion channel receptors and uses thereof (2024-01-30),
6. 11655304 - Antibody and checkpoint inhibitor combination therapy (2023-05-23),
7. 11478445 - Method for treating acute myeloid leukemia (2022-10-25),
8. 11384085 - Modulators of ion channel receptors and uses thereof (2022-07-12),
9. 10954231 - Anxiolytic compounds (2021-03-23),
10. 10745487 - Method of treating cancer by administering an anti-LGR5 monoclonal antibody (2020-08-18),
11. 10598653 - Methods of blocking cancer stem cell growth (2020-03-24),
12. 10564162 - Predictive biomarkers (2020-02-18),
13. 10520508 - Predictive baseline biomarkers for use of vascular disrupting agents (2019-12-31),
14. 10358500 - Humanized antibodies that bind LGR5 (2019-07-23),
15. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),
Company Overview
Bionomics Inc. is a biotechnology company based in Thebarton, Australia, specializing in the development of innovative cancer therapeutics. The company focuses on creating therapeutic formulations that leverage advanced technologies such as ion channel modulators and monoclonal antibodies. Bionomics is dedicated to enhancing cancer treatment through predictive biomarkers and combination therapies, aiming to improve patient outcomes. Its research encompasses a range of core topics, including anxiolytic compounds and tubulin polymerisation inhibitors, positioning it at the forefront of cancer research.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Bionomics Inc. USPTO Patent Assignee Logo
64 Patents

#1 in Thebarton

#47 in Australia

#11,484 in the World

Thebarton, AU
Thebarton, Australia

Bionomics Inc.

Forward Citations = 194

91 inventors:

goldMedal Bernard Luke Flynn (25 out of 27 patents)

silverMedal Dharam Paul (16 out of 19 patents)

bronzeMedal Jonathan Bayldon Baell (13 out of 29 patents)

4.  Gabriel Kremmidiotis (13 out of 13 patents)

5.  Andrew John Harvey (12 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bionomics Inc.. Retrieved from https://idiyas.com/company/bionomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…